Grand Ballroom I and II

8:00 am Registration & Coffee Room Networking

9:15 am Chair’s Opening Remarks

Lessons Learned from Clinical Case Studies to Fast Track Your Pipelines to Clinical Success

9:30 am Donor Derived Gamma-Delta T Cells; Path Towards Sold Tumor Therapies

Synopsis

  • Reviewing gamma-delta T cells; nonrestrictive lymphocytes that are thought to be attractive for allogeneic therapies
  • Outlining our INB-100 phase I program, which is the first to have delivered a large bolus of ex-vivo expanded and mismatched gamma-delta
    T cells into lymphodepleted leukemia patients
  • Providing safety data to advance our donor derived INB-400 program into the solid tumor setting

10:00 am Allogeneic NK-92 Cells: Advancing from Pre-Clinical Development to Clinical Application

Synopsis

  • Recapping the pre-clinical development of NK-92 and its clonal ‘offsprings’
  • Showcasing the outcome of first clinical studies
  • Reviewing novel NK-92 based variants expressing FcR, CARs and immune modulators

10:30 am Characterized Starting Materials for Accelerated and Scalable Allogeneic Cell Therapies

Synopsis

  • Leveraging access to highly annotated diseased biomaterials for enhanced target discovery
  • Outline how characterized donor source materials can impact consistency from process development to manufacturing
  • Incorporating multiomic analytics of the cell-based starting materials to enhance downstream processing

11:00 am Morning Refreshment Break & Structured Networking

Synopsis

As the allogeneic community is reunited, this valuable session will ensure you can reconnect with your peers in the room to make new and lasting connections. Also, don’t forget to enjoy some refreshments before we split off into the four different tracks: pre-clinical, translation, manufacturing and supply/storage.

5:45 pm Closing Remarks & Close of Conference

6:00 pm Drinks Reception

Synopsis

Taking place in the Exhibition Room